Page results
-
Initial results from an early phase study testing the safety and efficacy of a new drug for multiple myeloma have shown a 100 per cent overall response rate in patients with recurrent disease who were given the clinically recommended dose of the investigational drug.
-
A new toolkit to support babies, children and young people in healthcare access high quality health play services was launched at UCLH last week with UCLH chief nurse Vanessa Sweeney welcoming visitors from NHS England and the play charity Starlight.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
T16 North is a specialist adult haematology inpatient ward dedicated to providing high-quality care for patients with a wide range of blood disorders.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
This page is for patients receiving steroids for immunotherapy toxicity.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
UCLH Charity is delighted to announce a generous £1.5 million donation from the Bukhman Philanthropies.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology